Featured Articles
Dutch company ProQR announces the receipt of FDA authorisation to initiate Phase I/II study for Leber congenital amaurosis, type 10 (LCA10)
Dutch biotechnology company ProQR Therapeutcis N.V., (NASDAQ:PRQR), Leiden, The Netherlands, has announced the receipt of “fast-track” designation from the FDA for their clinical stage development of “QR-110”, an experimental gene editing treatment for Leber’s congenital amaurosis (LCA), type 10. Fast track designation is granted by the FDA to sponsors of treaments under development for serious […]
Read full storyUK multicentre real-world study demonstrates a sharp increase in diabetic macular oedema following cataract surgery
Research conducted on behalf of the UK Diabetic Retinopathy Electronic Medical Record (UK DR EMR) Users Group has shown that the rate of developing “treatment-requiring” diabetic macular oedema (DMO), following cataract surgery, increases dramatically, peaking in the 3-6 months’ postoperative period. In addition, the research demonstrated that patients with moderate and severe non-proliferative diabetic retinopathy (NPDR) […]
Read full storySwiss research team demonstrates changes of the intestinal mircobiome may be associated with age-related macular degeneration (AMD)
A research project conducted at the University of Bern, led by Dr. Martin S. Zinkernagel, Dr. Denise C. Zysset-Burri and Prof. Dr. Dr. Sebastian Wolf, has demonstrated that the composition of the intestinal microbiome in patients with AMD, compared to controls, indicates an enrichment of certain microbial genera. The finding may open a significant field […]
Read full story